EA038337B1 - Ингибиторы ezh2 для лечения лимфомы - Google Patents

Ингибиторы ezh2 для лечения лимфомы Download PDF

Info

Publication number
EA038337B1
EA038337B1 EA201692285A EA201692285A EA038337B1 EA 038337 B1 EA038337 B1 EA 038337B1 EA 201692285 A EA201692285 A EA 201692285A EA 201692285 A EA201692285 A EA 201692285A EA 038337 B1 EA038337 B1 EA 038337B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ezh2
subject
nhl
lymphoma
treatment
Prior art date
Application number
EA201692285A
Other languages
English (en)
Russian (ru)
Other versions
EA201692285A1 (ru
EA201692285A8 (ru
Inventor
Хайке Кайльхак
Лоун Оттесен
Лариса Рейдерман
Сара К. Натсон
Л. Дэниелл Джонстон
Original Assignee
Эпизим, Инк.
Эйсай Ар Энд Ди Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпизим, Инк., Эйсай Ар Энд Ди Менеджмент Ко., Лтд. filed Critical Эпизим, Инк.
Publication of EA201692285A1 publication Critical patent/EA201692285A1/ru
Publication of EA201692285A8 publication Critical patent/EA201692285A8/ru
Publication of EA038337B1 publication Critical patent/EA038337B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201692285A 2014-06-17 2015-06-17 Ингибиторы ezh2 для лечения лимфомы EA038337B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462013522P 2014-06-17 2014-06-17
US201462036265P 2014-08-12 2014-08-12
PCT/US2015/036310 WO2015195848A1 (en) 2014-06-17 2015-06-17 Ezh2 inhibitors for treating lymphoma

Publications (3)

Publication Number Publication Date
EA201692285A1 EA201692285A1 (ru) 2017-06-30
EA201692285A8 EA201692285A8 (ru) 2018-01-31
EA038337B1 true EA038337B1 (ru) 2021-08-11

Family

ID=54936086

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692285A EA038337B1 (ru) 2014-06-17 2015-06-17 Ингибиторы ezh2 для лечения лимфомы

Country Status (21)

Country Link
US (5) US10166238B2 (ko)
EP (2) EP4252851A3 (ko)
JP (1) JP6779793B2 (ko)
KR (2) KR102497728B1 (ko)
CN (2) CN113289022A (ko)
AU (3) AU2015277139A1 (ko)
BR (1) BR112016029492A2 (ko)
CA (1) CA2952074C (ko)
DK (1) DK3157527T3 (ko)
EA (1) EA038337B1 (ko)
ES (1) ES2948442T3 (ko)
FI (1) FI3157527T3 (ko)
HU (1) HUE062158T2 (ko)
IL (3) IL285201B2 (ko)
LT (1) LT3157527T (ko)
MX (2) MX2021007651A (ko)
PL (1) PL3157527T3 (ko)
PT (1) PT3157527T (ko)
SG (2) SG11201610273VA (ko)
SI (1) SI3157527T1 (ko)
WO (1) WO2015195848A1 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (en) 2010-06-23 2011-12-29 Morin Ryan D Biomarkers for non-hodgkin lymphomas and uses thereof
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
MX2021007651A (es) * 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
CA2963149A1 (en) 2014-10-16 2016-04-21 Epizyme, Inc. Method for treating cancer
AU2015350108B2 (en) * 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
CN107635965A (zh) 2015-06-10 2018-01-26 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
US10493076B2 (en) 2015-08-24 2019-12-03 Epizyme, Inc. Method for treating cancer
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
AU2017211331A1 (en) * 2016-01-29 2018-06-07 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
WO2017218953A1 (en) 2016-06-17 2017-12-21 Epizyme, Inc. Ezh2 inhibitors for treating cancer
CN110475557B (zh) * 2017-01-20 2023-06-20 星座制药公司 固体分散体
WO2018183885A1 (en) 2017-03-31 2018-10-04 Epizyme, Inc. Combination therapy for treating cancer
JP2020522687A (ja) 2017-06-02 2020-07-30 エピザイム,インコーポレイティド 癌を処置するためのezh2阻害剤の使用
US20210161883A1 (en) * 2017-07-10 2021-06-03 Constellation Pharmaceuticals, Inc. Ezh2 inhibitor-induced gene expression
JP7399079B2 (ja) 2017-09-05 2023-12-15 エピザイム,インコーポレイティド 癌を処置するための併用療法
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
CN110950834A (zh) * 2019-11-26 2020-04-03 济南大学 新型eed-ezh2相互作用小分子抑制剂的确定和评价

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138361A1 (en) * 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer
WO2014071109A1 (en) * 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2614369B1 (en) 2010-09-10 2016-02-03 Epizyme, Inc. Method for determining the suitability of inhibitors of human ezh2 in treatment
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JP2014534178A (ja) 2011-09-30 2014-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 癌の処置方法
BR112014025508B1 (pt) 2012-04-13 2020-11-17 Eisai R&D Management Co., Ltd. forma de sal de um inibidor de histona metiltransferase ezh2 humana
IL289300B2 (en) 2012-04-13 2024-05-01 Epizyme Inc Combined treatment for cancer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
MY180311A (en) 2012-10-15 2020-11-28 Epizyme Inc Substituted benzene compounds
US20140120083A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20150283142A1 (en) 2013-03-15 2015-10-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5
RU2019134551A (ru) * 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP3022195A2 (en) 2013-07-19 2016-05-25 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3055422B1 (en) 2013-10-09 2018-11-14 Roche Diagnostics GmbH Methods and compositions for detecting a mutation in the human ezh2 gene
EP4324525A3 (en) 2013-10-16 2024-07-17 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
JP2016533364A (ja) 2013-10-18 2016-10-27 エピザイム,インコーポレイティド 癌を処置する方法
IL282741B2 (en) 2013-12-06 2024-01-01 Epizyme Inc Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
MX2021007651A (es) 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.
CA2966336A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
AU2015350108B2 (en) 2014-11-17 2021-04-08 Eisai R&D Management Co., Ltd. Method for treating cancer
JP6544507B2 (ja) 2015-02-09 2019-07-17 日本精機株式会社 ヘッドアップディスプレイ装置
CN107635965A (zh) 2015-06-10 2018-01-26 Epizyme股份有限公司 用于治疗淋巴瘤的ezh2抑制剂
KR20170095656A (ko) 2016-02-15 2017-08-23 동부대우전자 주식회사 방열구조를 갖는 세탁기

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138361A1 (en) * 2012-03-12 2013-09-19 Epizyme, Inc. Inhibitors of human ezh2, and methods of use thereof
WO2014062720A2 (en) * 2012-10-15 2014-04-24 Epizyme, Inc. Methods of treating cancer
WO2014071109A1 (en) * 2012-11-01 2014-05-08 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dyer M.J.S. et al. (1990) A New Human B-Cell Non-Hodgkin's Lymphoma Cell Line (Karpas 422) Exhibiting Both t(14;18) and t(4;11) Chromosomal Transolcations, Blood 75: 709-714, Abstract; Table 2 *
Hassan U. et al. (2012) Prognostic Sub-Grouping of Diffuse Large B-Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy. Asian Pacific Journal of Cancer Prevention. 13: 1341-1347, Abstract; Table 1 *
Knutson S.K. et al. (2014) Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma. Molecular Cancer Therapeutics 13: 842-854. Published online 21 February, 2014, Abstract; Pages 842-843; Figures 3&4 *
View of NCT01897571 on 2014_03_27 on ClinicalTrials.gov Archive. Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With В Cell Lymphomas. [retrieved from internet on 9 July 2015] <URL: https://clinicaltrials.gov/archive/NCT01897571/2014_03_27> (published 27 March 2014) Brief Summary; Detailed Description *

Also Published As

Publication number Publication date
CN106999498B (zh) 2021-06-08
WO2015195848A1 (en) 2015-12-23
DK3157527T3 (da) 2023-07-03
MX2021007651A (es) 2021-08-11
PT3157527T (pt) 2023-06-30
US20200022987A1 (en) 2020-01-23
EP3157527A1 (en) 2017-04-26
SG11201610273VA (en) 2017-01-27
WO2015195848A8 (en) 2016-07-07
KR102497728B1 (ko) 2023-02-09
AU2022263523A1 (en) 2022-12-08
CA2952074C (en) 2022-08-30
AU2020244382A1 (en) 2020-10-29
US20200323866A1 (en) 2020-10-15
HUE062158T2 (hu) 2023-10-28
EP3157527B1 (en) 2023-05-24
BR112016029492A2 (pt) 2017-10-17
EP3157527A4 (en) 2018-05-23
ES2948442T3 (es) 2023-09-12
EP4252851A2 (en) 2023-10-04
US20170216300A1 (en) 2017-08-03
LT3157527T (lt) 2023-07-25
EA201692285A1 (ru) 2017-06-30
US11642347B2 (en) 2023-05-09
CN106999498A (zh) 2017-08-01
JP6779793B2 (ja) 2020-11-04
KR20230031963A (ko) 2023-03-07
IL285201B1 (en) 2024-01-01
AU2015277139A1 (en) 2016-12-22
EA201692285A8 (ru) 2018-01-31
FI3157527T3 (fi) 2023-07-25
IL309539A (en) 2024-02-01
JP2017518334A (ja) 2017-07-06
IL285201B2 (en) 2024-05-01
CA2952074A1 (en) 2015-12-23
SG10201811128RA (en) 2019-01-30
AU2020244382B2 (en) 2022-08-04
US10166238B2 (en) 2019-01-01
MX2016016744A (es) 2017-11-30
US20240058348A1 (en) 2024-02-22
IL285201A (en) 2021-08-31
US20190175604A1 (en) 2019-06-13
PL3157527T3 (pl) 2023-08-07
KR20170052558A (ko) 2017-05-12
SI3157527T1 (sl) 2023-09-29
CN113289022A (zh) 2021-08-24
EP4252851A3 (en) 2023-11-22
IL249438A0 (en) 2017-02-28
NZ727108A (en) 2023-09-29

Similar Documents

Publication Publication Date Title
EA038337B1 (ru) Ингибиторы ezh2 для лечения лимфомы
US20220160721A1 (en) Methods of treating cancer
US20210121470A1 (en) Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor
JP7045985B2 (ja) Ezh2阻害剤を用いた髄芽腫の処置方法
JP2018524298A (ja) リンパ腫を処置するためのezh2阻害剤
US20230181549A1 (en) Use of ezh2 inhibitors for treating cancer
WO2018128664A2 (en) 18f-labeled compounds for pet imaging and uses thereof
NZ727108B2 (en) Ezh2 inhibitors for treating lymphoma